No bidding war for Loxo, so did Lilly overpay? Don’t rush to judgment, analysts say

No bidding war for Loxo, so did Lilly overpay? Don’t rush to judgment, analysts say

Source: 
Fierce Pharma
snippet: 

The lack of competing bids for Loxo Oncology raises questions about whether Eli Lilly could have won the deal without offering a 68% premium for the maker of targeted cancer drugs. But a closer look at the SEC documents describing the deal suggests that's not necessarily true, analysts say.